LATEST ARTICLES

8th Plenary Meeting EHDN 2014 Barcelona: 19-21 settembre 2014 – Report

Annarita Bentivoglio* - Marina Frontali** Si è appena concluso l’ottavo meeting plenario del Network Europeo per la Malattia di Huntington. Oltre 900 partecipanti: l’incontro più numeroso...

Fatal cellular malfunction identified in Huntington’s disease

Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities...

Roche announces details of its ‘pivotal’ huntingtin-lowering study

The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington's disease t’s a time of huge developments in the...

New £9.1m contract with a top 10 global pharmaceutical company

Specialist medical imaging services for a Phase III Huntington’s disease clinical trial, highlighting the value of IXICO’s data science expertise in neuroscience drug development. IXICO...

Predict the onset and course of Huntington’s disease

The origin of this incurable nervous disease lies in minute fibers formed by chains of the huntingtin protein MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE IN...

Study Suggests Potential Therapy for Huntington’s Disease

A new study published in the Proceedings of the National Academy of Sciences (PNAS) suggests that Huntington’s disease may take effect much earlier in life than...

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease

European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit...